444 related articles for article (PubMed ID: 20572029)
41. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K
Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186
[TBL] [Abstract][Full Text] [Related]
42. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.
Woehrer S; Hejna M; Skrabs C; Drach J; Zielinski CC; Jaeger U; Raderer M
Oncology; 2005; 69(6):499-502. PubMed ID: 16424679
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
[TBL] [Abstract][Full Text] [Related]
44. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894
[TBL] [Abstract][Full Text] [Related]
45. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
46. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma.
Kato J; Mori T; Yokoyama K; Tsukada Y; Ueda T; Shimizu T; Okamoto S
Bone Marrow Transplant; 2011 Jul; 46(7):923-8. PubMed ID: 20972471
[TBL] [Abstract][Full Text] [Related]
49. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
50. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
51. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
[TBL] [Abstract][Full Text] [Related]
52. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
[TBL] [Abstract][Full Text] [Related]
53. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
[TBL] [Abstract][Full Text] [Related]
54. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
55. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Harting R; Venugopal P; Gregory SA; O'brien T; Bogdanova E
Clin Lymphoma Myeloma; 2007 May; 7(6):406-12. PubMed ID: 17621406
[TBL] [Abstract][Full Text] [Related]
57. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB; Lauritzsen GF; Kvalheim G; Kolstad A; Fagerli UM; Maisenhölder M; Østenstad B; Fluge Ø; Delabie J; Aarset H; Liestøl K; Holte H
Br J Haematol; 2011 Mar; 152(5):600-10. PubMed ID: 21241276
[TBL] [Abstract][Full Text] [Related]
58. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
59. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
[TBL] [Abstract][Full Text] [Related]
60. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Machover D; Delmas-Marsalet B; Misra SC; Gumus Y; Goldschmidt E; Schilf A; Frénoy N; Emile JF; Debuire B; Guettier C; Farrokhi P; Boulefdaoui B; Norol F; Parquet N; Ulusakarya A; Jasmin C
Ann Oncol; 2001 Oct; 12(10):1439-43. PubMed ID: 11762817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
